Perioperative chemotherapy does not improve disease free survival in upper tract urothelial carcinoma: A population based analysis

2017 ◽  
Vol 16 (3) ◽  
pp. e2011-e2015
Author(s):  
H. Goldberg ◽  
Z. Klaassen ◽  
T. Chandrasekar ◽  
R. Hamilton ◽  
G. Kulkarni ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Disease Free Survival ◽  
Population Based ◽  
Upper Tract Urothelial Carcinoma ◽  
Perioperative Chemotherapy ◽  
Free Survival ◽  
Upper Tract ◽  
Disease Free

Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma

2012 ◽  
Vol 31 (1) ◽  
pp. 5-11 ◽  
Author(s):  
Harun Fajkovic ◽  
Eugene K. Cha ◽  
Evanguelos Xylinas ◽  
Michael Rink ◽  
Armin Pycha ◽  
...  
Keyword(s):  
Overall Survival ◽  
Urothelial Carcinoma ◽  
Disease Free Survival ◽  
Upper Tract Urothelial Carcinoma ◽  
Free Survival ◽  
Upper Tract ◽  
Disease Free

392 DISEASE-FREE SURVIVAL AS A SURROGATE FOR 5-YEAR OVERALL SURVIVAL IN UPPER TRACT UROTHELIAL CARCINOMA

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Eugene K. Cha ◽  
Harun Fajkovic ◽  
Michael Rink ◽  
Armin Pycha ◽  
Allison Dunning ◽  
...  
Keyword(s):  
Overall Survival ◽  
Urothelial Carcinoma ◽  
Disease Free Survival ◽  
Upper Tract Urothelial Carcinoma ◽  
Free Survival ◽  
Upper Tract ◽  
Disease Free

scholarly journals Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis

Oncotarget ◽  
2018 ◽  
Vol 9 (27) ◽  
pp. 18797-18810 ◽  
Author(s):  
Hanan Goldberg ◽  
Zachary Klaassen ◽  
Thenappan Chandrasekar ◽  
Rashid Sayyid ◽  
Girish S. Kulkarni ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Population Based ◽  
Upper Tract Urothelial Carcinoma ◽  
Perioperative Chemotherapy ◽  
Upper Tract

scholarly journals Prognostic Significance of Primary Tumor Location in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Retrospective, Multi-Center Cohort Study in Taiwan

2020 ◽  
Vol 9 (12) ◽  
pp. 3866
Author(s):  
Lian-Ching Yu ◽  
Chao-Hsiang Chang ◽  
Chi-Ping Huang ◽  
Chao-Yuan Huang ◽  
Jian-Hua Hong ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Tumor Location ◽  
Upper Tract Urothelial Carcinoma ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Upper Tract ◽  
Ureteral Tumor ◽  
Worse Prognosis

We sought to examine the effect of tumor location on the prognosis of patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). This retrospective study came from the Taiwan UTUC Collaboration Group, which consisted of 2658 patients at 15 institutions in Taiwan from 1988 to 2019. Patients with kidney-sparing management, both renal pelvic and ureteral tumors, as well as patients lacking complete data were excluded; the remaining 1436 patients were divided into two groups: renal pelvic tumor (RPT) and ureteral tumor (UT), with 842 and 594 patients, respectively. RPT was associated with more aggressive pathological features, including higher pathological T stage (p < 0.001) and the presence of lymphovascular invasion (p = 0.002), whereas patients with UT often had synchronous bladder tumor (p < 0.001), and were more likely to bear multiple lesions (p = 0.001). Our multivariate analysis revealed that UT was a worse prognostic factor compared with RPT (overall survival: HR 1.408, 95% CI 1.121–1.767, p = 0.003; cancer-specific survival: HR 1.562, 95% CI 1.169–2.085, p = 0.003; disease-free survival: HR 1.363, 95% CI 1.095–1.697, p = 0.006; bladder-recurrence-free survival: HR 1.411, 95% CI 1.141–1.747, p = 0.002, respectively). Based on our findings, UT appeared to be more malignant and had a worse prognosis than RPT.

Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review

2017 ◽  
Vol 35 (9) ◽  
pp. 1401-1407 ◽  
Author(s):  
Atiqullah Aziz ◽  
◽  
Jakub Dobruch ◽  
Kees Hendricksen ◽  
Luis A. Kluth ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Upper Tract Urothelial Carcinoma ◽  
Perioperative Chemotherapy ◽  
Comprehensive Review ◽  
Upper Tract

scholarly journals LGALS4 as a Prognostic Factor in Urothelial Carcinoma of Bladder Affects Cell Functions

2019 ◽  
Vol 18 ◽  
pp. 153303381987660 ◽  
Author(s):  
Yu Ding ◽  
Qifeng Cao ◽  
Chen Wang ◽  
Huangqi Duan ◽  
Haibo Shen
Keyword(s):  
Urothelial Carcinoma ◽  
Survival Curve ◽  
Disease Free Survival ◽  
Hub Genes ◽  
Free Survival ◽  
Polymerase Chain ◽  
Carcinoma Of The Bladder ◽  
Bladder Cells ◽  
And Migration ◽  
Disease Free

Background: To identify the hub genes related to urothelial carcinoma of the bladder prognosis and to understand their underlying mechanism. Methods: The expression profiles of 18 pairs of urothelial carcinoma of the bladder patient tissue and paired adjacent tissue obtained from the Cancer Genome Atlas were performed. Weighted gene coexpression network analysis was employed to screen gene modules and hub genes with significant differential expressions in urothelial carcinoma of the bladder. The hub genes expression in urothelial carcinoma of the bladder tissues was validated by reverse transcription-quantitative polymerase chain reaction. The overall survival curve and disease-free survival curve of prognostic factor ( LGALS4) were plotted using the Kaplan-Meier method. Furthermore, LGALS4 messenger RNA and protein expression were also assessed in 2 urothelial carcinoma of the bladder cell lines (T24 and 5637) by quantitative reverse transcription–polymerase chain reaction and Western blot. The functions of urothelial carcinoma of the bladder cells with transfected pcDNA3.1- LGALS4 were identified through MTT assay, plate clone formation assay, flow cytometry, and cell migration experiments. Results: LGALS4 was the hub gene of pink module and it was related to prognosis. Higher LGALS4 expression predicted higher probabilities of overall survival and disease-free survival. Overexpression of LGALS4 in urothelial carcinoma of the bladder cells suppressed cell viability and migration but induced apoptosis. Conclusion: LGALS4 played a critical role in the progression of urothelial carcinoma of the bladder and held a promise to be the biomarker for diagnosis and treatment of urothelial carcinoma of the bladder. It predicted good prognosis of urothelial carcinoma of the bladder and restrained the growth and migration of urothelial carcinoma of the bladder cells.

scholarly journals Ecoendoscopia en la estadificación del cáncer de esófago y de estómago

2021 ◽  
Vol 113 (1) ◽  
pp. 32-42
Author(s):  
Martín Galvarini Recabarren ◽  
◽  
Francisco Schlottmann ◽  
C. Agustín Angeramo ◽  
Javier Kerman Cabo ◽  
...  
Keyword(s):  
Overall Survival ◽  
Neoadjuvant Therapy ◽  
Preoperative Staging ◽  
Disease Free Survival ◽  
Perioperative Chemotherapy ◽  
Free Survival ◽  
Causes Of Mortality ◽  
Node Metastases ◽  
Disease Free

Background: Gastric adenocarcinoma (GAC) and esophageal adenocarcinoma (EAC) are one of the leading causes of mortality from gastrointestinal cancer worldwide. Endoscopic ultrasound (EUS) has proved to be a valuable tool for preoperative staging of GAC and EAC in selected cases. Objective: The aim of this study was to evaluate the usefulness of EUS for staging of EAC and GAC and selecting patients who are candidates for neoadjuvant therapy, as compared with the previous stage before the implementation of EUS, in a surgical center in Argentina. Material and methods: Consecutive patients with EAC and GAC between 2013-2019 were included. Patients with criteria of unresectable cancer or who underwent emergency surgery were excluded. The sample was divided into four groups G1 and G2 (EAC with and without EUS, respectively) and G3 and G4 (GAC with and without EUS, respectively). The clinical and anatomopathological variables and survival were evaluated in all the groups. Results: A total of 89 patients were included, 40 with EAC (30 in G1 and 10 in G2, and 49 with GAC, 20 in G3 and 29 in G4. Of the patients undergoing EUS staging in G1, 23 (75%) received neoadjuvant therapy vs. 2 patients in G2 (20%) (P ≤ 0.005). Eight patients (40%) in G3 and 2 (7%) in G4 received perioperative chemotherapy (P ≤ 0.005). Lymph node metastases were observed in 9 (30%) of surgical specimens of EAC in G1 and in 60% in G2 (P ≤ 0.005), and in 45% in G3 and G4. After a mean follow-up of 36 months (6-72), we observed a non-significant trend toward higher overall survival and disease-free survival in patients undergoing EUS staging. Conclusion: EUS for preoperative staging pf EAC and GAC is a useful tool. Although the use of EUS use may be a challenging task in many centers in Argentina, future efforts are needed to include this test in selected cases for staging patients with these types of cancers

820 A population-based competing-risks analysis of survival after nephroureterectomy for upper tract urothelial carcinoma

2013 ◽  
Vol 12 (1) ◽  
pp. e820-e821
Author(s):  
A. Abdo ◽  
F. Roghmann ◽  
A. Becker ◽  
M. Meskawi ◽  
P.I. Karakiewicz ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Competing Risks ◽  
Population Based ◽  
Upper Tract Urothelial Carcinoma ◽  
Upper Tract ◽  
Competing Risks Analysis
Sign in / Sign up

Export Citation Format

Share Document